R-Biopharm starts RIDA qLine® Allergy External Quality Assessment. This new tool will help to ensure the quality of the testing procedures in laboratories using RIDA qLine® Allergy and the [...]
Chronic inflammatory bowel disease (IBD) is characterized by recurring and often ongoing flares. The most common forms of IBD are Crohns disease and Ulcerative colitis.
TNFalpha blocker are biologic agents, which are used for the treatment of inflammatory diseases such as Ulcerative Colitis, Crohns disease and Rheumatoid Arthritis. Infliximab as well as [...]
Molander et al. investigated if concentrations of fecal calprotectin can be used for predicting relaps after stopping TNFα blocking therapy in patients with Ulcerative Colitis and Morbus Crohn.
Study about first randomized, controlled testing shows that clinical treatment decisions based on therapeutic drug monitoring (TDM) is superior to dose-intensification strategy.
The RIDA®GENE real-time PCR assays for the detection of Influenza (RIDA®GENE Flu, RIDA®GENE Flu LC2.0, RIDA®GENE Flu & RSV) detect the currently circulating drift variant of influenza A (H3N2).
Ann Gils and her colleagues from KU Leuven evaluated if the biosimilars were equally well quantified as the original infliximab (IFX) drug in their clinically validated infliximab assay.
Community-acquired pneumonia (CAP) is the most common fatal infectious disease in western countries. Bacteria are the most common pathogens causing CAP, where one differentiates between typical [...]
RIDASCREEN® IFX Monitoring is an enzyme linked immunoassay intended for the quantitative determination of infliximab (IFX, anti-TNFα) in human serum and plasma.
